tbuckley/cabot-search huggingface dataset:
Towards equity in immunisation
Authors: Tammy Boyce, Amelie Gudorf, Catharina de Kat, Mark Muscat, Robb Butler, Katrine Bach Habersaat
Journal: Eurosurveillance (2019)

In the World Health Organization (WHO) European Region, differences in uptake rates of routine childhood immunisation persist within and among countries, with rates even falling in some areas. There has been a tendency among national programmes, policymakers and the media in recent years to attribute missed vaccinations to faltering demand or refusal among parents. However, evidence shows that the reasons for suboptimal coverage are multifactorial and include the social determinants of health. At the midpoint in the implementation of the European Vaccine Action Plan 2015–2020 (EVAP), national immunisation programmes should be aware that inequity may be a factor affecting their progress towards the EVAP immunisation targets. Social determinants of health, such as individual and household income and education, impact immunisation uptake as well as general health outcomes – even in high-income countries. One way to ensure optimal coverage is to make inequities in immunisation uptake visible by disaggregating immunisation coverage data and linking them with already available data sources of social determinants. This can serve as a starting point to identify and eliminate underlying structural causes of suboptimal uptake. The WHO Regional Office for Europe encourages countries to make the equitable delivery of vaccination a priority.
Societies.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of Aerosol Particle Leak and Standard Surgical Mask Fit With 3 Elastomeric Harness Designs
Authors: Jeannette Ingabire, Hannah McKenney, Charles Sebesta, Krishna Badhiwala, Caleb Kemere, Sahil Kapur, Jacob T. Robinson
Journal: JAMA Network Open (2022)

This comparative effectiveness study evaluates aerosol particle leak and standard surgical mask fit with 3 elastomeric harness designs tested on mannequin heads and human participants using US Occupational Safety and Health Administration N95 fit factor requirements.
CRISPR/Cas9-mediated KLKB1 Gene Editing and Serum Kallikrein Reduction by NTLA-2002 Remains Durable in Humanized Mice Following Liver Regeneration after Partial Hepatectomy
Authors: Kathryn Walsh, Peter Cottingham, Cindy Shaw, Jonathan Phillips, Jessica Seitzer, Chris Blanchard, Noah Gardner, Vinita Doshi, Kristy Wood, Samantha Soukamneuth, Bo Han, Shreelekha Jaligama, Riley Cole, Sucharitha Parthasarathy, Dmitriy Kryukov, James Butler
Journal: Journal of Allergy and Clinical Immunology (2022)
Hepatotrophic Factors
Authors: R. P. H. Thompson
Journal: Gut (1978)

enteropathy and another almost as short on malabsorption syndromes.The choice of references, especially in the first part, is strangely arbitrary.The section on para- sitic diseases is better organised and pro- vides much useful data in compact form, and the last pages give a useful summary of the main antiparasitic drugs, with data on dosage and toxicity.H. P.
<i>Notes from the Field:</i> COVID-19 Vaccination Among Persons Living with Diagnosed HIV Infection — New York, October 2021
Authors: James M. Tesoriero, Wendy Patterson, Demetre Daskalakis, Joyce Chicoine, Johanne Morne, Sarah Braunstein, Deepa T. Rajulu, Eli Rosenberg
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

COVID-19 cases and 58,000 COVID-19-associated deaths occurred in the state of New York.*New York has the highest U.S. per capita rate of persons living with diagnosed HIV infection (PLWDH), † and population-level analyses adjusting for age, sex, and region have shown that PLWDH are more likely to be hospitalized for and to experience an in-hospital death from COVID-19 than are those not known to be PLWDH (1).CDC considers PLWDH who have a low CD4 cell count or who are not receiving HIV treatment to be at elevated risk for severe COVID-19-associated outcomes (2).COVID-19 vaccines have been shown to be effective against symptomatic infection and hospitalization in New York, including during the period when the B.1.617.2 (Delta) and B.1.1.529(Omicron) variants of SARS-CoV-2, the virus that causes predominated (3,4).PLWDH were an early priority group for vaccine eligibility, in part because of elevated COVID-19 risks.However, little is known about vaccination coverage among PLWDH.Data from the New York State HIV surveillance registry were matched with the New York City Citywide Immunization Registry and New York State Immunization Information System.A deterministic matching algorithm § was used to ascertain, as of October 24, 2021, COVID-19 vaccination status for PLWDH aged ≥18 years who were alive on December 31, 2020.Because death data were available only through December 2020, deaths in PLWDH reported in previous years in New York State, including 2020, were used to estimate that this analysis likely includes 500-1,000 PLWDH who died during the early part of 2021, precluding the opportunity for these decedents to begin or complete vaccination.
Medical and Surgical Report of the Presbyterian Hospital in the City of New York
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Counting Advanced Precancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity
Authors: Uri Ladabaum, Timothy R Church, Ziding Feng, David F Ransohoff, Robert E Schoen
Journal: JNCI Journal of the National Cancer Institute (2022)

The landmark Centers for Medicare & Medicaid Services (CMS) decision memo on blood-based biomarkers to screen for colorectal cancer (CRC) sets thresholds of 74% or higher for sensitivity and 90% or higher for specificity for CRC. This approach does not consider detection of advanced precancerous lesions as true positives. We contrasted the impact of counting advanced precancerous lesions as true vs false positives and projected CRC outcomes under contrasting tests in a validated model. A test with the threshold performance set by CMS decreased CRC incidence by 30% and CRC mortality by 48% in individuals aged 45 years. If this test also detected advanced precancerous lesions with 30% sensitivity, CRC incidence decreased by 45% and mortality by 58%, but the CRC specificity of the test of only 88% would not satisfy the CMS threshold. CMS should reconsider its definition of threshold specificity for CRC screening biomarkers. Future coverage determinations on biomarkers to screen for cancer should consider detection of relevant precursor lesions and projected outcomes.
Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States
Authors: Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, Ignacio Garrido-Laguna
Journal: Journal of the National Comprehensive Cancer Network (2022)

BRAF mutations portend a poor prognosis in metastatic colorectal cancer (mCRC). Whether these patients may benefit from more aggressive frontline chemotherapy with a triplet regimen such as FOLFOXIRI remains unclear. We used real-world data from a cohort of patients in the United States to assess the BRAF testing rate, determine the prevalence of FOLFOXIRI use, and compare survival outcomes in mCRC, stratified by BRAF mutation status and first-line therapy.A nationwide electronic health record-derived deidentified database was reviewed for patients diagnosed with mCRC between 2013 and 2018. Those with documented BRAF mutation testing who received standard first-line therapy were included. Kaplan-Meier estimates with corresponding log-rank tests and Cox proportional hazards modeling compared survival outcomes stratified by BRAF status and first-line therapy.Of 4,457 included patients, 3,991 (89.5%) had BRAF wild-type (BRAFwt) and 466 (10.5%) had BRAF-mutated (BRAFmt) mCRC. Median overall survival (OS) was 15.4 months in the BRAFmt group versus 28.1 months in the BRAFwt group (hazard ratio [HR], 0.48; 95% CI, 0.41-0.56; P<.001). Only 3% of patients with BRAF mutations received first-line FOLFOXIRI ± bevacizumab, with a median OS of 13.8 months compared with 15.5 months in those treated with doublet chemotherapy ± bevacizumab (P=.38). In patients with BRAF mutations, propensity-weighted analysis did not detect a significant improvement in OS with FOLFIRI + bevacizumab (HR, 0.90; 95% CI, 0.58-1.39; P=.63) or FOLFOX/CAPEOX + bevacizumab (HR, 0.81; 95% CI, 0.52-1.26; P=.35) versus doublet chemotherapy alone. In 2018, only 56% of patients diagnosed with mCRC had documented BRAF testing at any time.This real-world data analysis confirms the negative prognostic impact of BRAF mutations in mCRC and suggests that FOLFOXIRI has not been widely adopted in the United States. The proportion of patients with documented BRAF testing in this real-world population was low at 56%. We were unable to show any significant difference in OS of patients with BRAFmt mCRC based on the first-line therapy received.
Abstract Book for the 2nd Sickle Cell &amp; Thalassaemia Virtual Conference
Journal: HemaSphere (2022)

Log in or Register Get new issue alertsGet alerts Submit your manuscript Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Register Login Articles & Issues Latest ArticlesCurrent IssuePrevious Issues Subject Areas Cell and Gene TherapiesHematopoiesisLymphoid MalignanciesMyeloid MalignanciesRed Cell and Iron MetabolismThrombosis and HemostasisView All Featured Content Latest ArticlesReviews & ControversiesGuidelinesHemaTopicsHemaBitesEHA Research RoadmapCAR T-CellGene TherapyCOVID-19Biosimilars For Authors Instructions for Authors Submit Your PaperBenefits for AuthorsOpen Access Editorial, Legal, and Ethical PoliciesLanguage Editing Services About Us About the JournalEditorial BoardAffiliated SocietyReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
INFECTION IN CHILDREN.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lipidomic Analysis of Epithelium Reveals Unique Sphingolipid Profile in Eosinophilic Esophagitis
Authors: Melinda Braskett, Elena Goleva, Irina Bronova, Gautam Nagendra, Warren Mikako, Harry Cynamon, Vrinda Bhardwaj, Ramon Durazo-Arvizu, Peck Ong, Donald Leung, Evgeny Berdyshev
Journal: Journal of Allergy and Clinical Immunology (2022)
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
Authors: Christine E Brown, Analiz Rodriguez, Joycelynne Palmer, Julie R Ostberg, Araceli Naranjo, Jamie R Wagner, Brenda Aguilar, Renate Starr, Lihong Weng, Timothy W Synold, Vivi Tran, Shelley Wang, Andreas Reik, Massimo D’Apuzzo, Julie A Ressler, Yuanyue Zhou, Matthew Mendel, Philip D Gregory, Michael C Holmes, Winson W Tang, Stephen J Forman, Michael C Jensen, Behnam Badie
Journal: Neuro-Oncology (2022)

Abstract Background Wide-spread application of chimeric antigen receptor (CAR) T cell therapy for cancer is limited by the current use of autologous CAR T cells necessitating the manufacture of individualized therapeutic products for each patient. To address this challenge, we have generated an off-the-shelf, allogeneic CAR T cell product for the treatment of glioblastoma (GBM), and present here the feasibility, safety, and therapeutic potential of this approach. Methods We generated for clinical use a healthy-donor derived IL13Rα2-targeted CAR+ (IL13-zetakine+) cytolytic T-lymphocyte (CTL) product genetically engineered using zinc finger nucleases (ZFNs) to permanently disrupt the glucocorticoid receptor (GR) (GRm13Z40-2) and endow resistance to glucocorticoid treatment. In a phase I safety and feasibility trial we evaluated these allogeneic GRm13Z40-2 T cells in combination with intracranial administration of recombinant human IL-2 (rhIL-2; aldesleukin) in six patients with unresectable recurrent GBM that were maintained on systemic dexamethasone (4-12 mg/day). Results The GRm13Z40-2 product displayed dexamethasone-resistant effector activity without evidence for in vitro alloreactivity. Intracranial administration of GRm13Z40-2 in four doses of 108 cells over a two-week period with aldesleukin (9 infusions ranging from 2500–5000 IU) was well tolerated, with indications of transient tumor reduction and/or tumor necrosis at the site of T cell infusion in four of the six treated research subjects. Antibody reactivity against GRm13Z40-2 cells was detected in the serum of only one of the four tested subjects. Conclusions This first-in-human experience establishes a foundation for future adoptive therapy studies using off-the-shelf, zinc-finger modified, and/or glucocorticoid resistant CAR T cells.
Antibiofilm and immunomodulatory resorbable nanofibrous filing for dental pulp regenerative procedures
Authors: Mauricio Gonçalves da Costa Sousa, Gabriela Conceição de Almeida, Danilo César Martins Mota, Rosiane Andrade da Costa, Simoni Campos Dias, Samuel Nunes Limberger, Frank Ko, Li Ting Lin, Evan F. Haney, Hashem Etayash, Beverlie Baquir, Michael J. Trimble, Ya Shen, Zheng Su, Markus Haapasalo, Daniel Pletzer, Letícia Chaves de Souza, Gláucia Schuindt Teixeira, Renato M. Silva, Robert E.W. Hancock, Octavio Luiz Franco, Taia Maria Berto Rezende
Journal: Bioactive Materials (2022)

Multifunctional scaffolds with host defense peptides designed for regenerative endodontics are desirable nanobiotechnological tools for dentistry. Here, different scaffolds were tested for use during the pulp revascularization process, including poly(vinyl alcohol)-PVA hydrogels or resins, collagen hydrogels and poly(vinyl alcohol) PVA/Chitosan (PVA/CS) nanofibers. Based on time to degradation (21 days), nanofibers were chosen to be incorporated with ciprofloxacin and IDR-1002 (each at 50 mg/g). Nanofibers containing ciprofloxacin and IDR-1002 had anti-biofilm activity against Enterococcus faecalis, Staphylococcus aureus and a multispecies oral biofilm, besides anti-inflammatory activities. The in vivo subcutaneous tissue response to tooth fragments filled with nanofibers demonstrated a pulp-like tissue formation, when compared to empty teeth fragments. Thus, we designed a strong antimicrobial, immunomodulatory and regenerative candidate for pulp revascularization and regeneration procedures.
Analgesia
Authors: Patrick Tracy
Journal: JAMA (1996)

<i>Analgesia</i>pursues the stated purpose of publishing "original research, reports, reviews, and mini-reviews involving rigorous ethical experimental studies on the basic mechanisms and therapeutics of pain relief." This international journal includes both basic and clinical research reports, although it seems weighted toward the former. The reports deal with many different aspects of the pain pathways (eg, anatomical, biochemical, molecular, pharmacological, and physiological), involve studies of neurotransmitter and neuromodulators, and investigate known and experimental analgesic and antinociceptive compounds. Each of the three issues examined contains two reviews and five to six original studies. The instructions to authors are concise and contain only relevant information. The editors do not specifically delineate their process of peer review. Submission-to-publication time averages only a few months, making the information available in a timely manner.<i>Analgesia</i>offers an attractive page layout that contributes to reading ease. All tables, figures, and illustrations are reproduced in black and
American Heart Month — February 2019
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Heart disease is the leading cause of death for men and women in the United States, and heart attacks are a major category of heart disease; someone in the United States has a heart attack every 40 seconds (1). February is American Heart Month, an ideal time to remind all adults to focus on their hearts and encourage them, their families, friends, and communities to learn the important signs and symptoms of heart attack and how to respond. Recognizing that someone might be having a heart attack and calling emergency services (9-1-1) are crucial for optimizing access to lifesaving emergency cardiac care and receipt of advanced treatments and improving survival. Five common symptoms of a heart attack are 1) pain or discomfort in the jaw, neck, or back; 2) feeling weak, lightheaded, or faint; 3) chest pain or discomfort; 4) pain or discomfort in the arms or shoulder; and 5) shortness of breath. If someone is suspected to be having a heart attack, 9-1-1 should be called immediately.
Housing Conditions and Access to Care for Children with Asthma During COVID-19 Pandemic in New York City
Authors: Kaoru Harada, Erin Thanik, Nicholas DeFelice, Jasmine Bhatia, Ray Lopez, Sergio Galvez, Moira Bixby, Elan Dayanov, Douglas Bush, Elizabeth Garland
Journal: Journal of Allergy and Clinical Immunology (2022)
Acute coronary syndromes
Authors: Adam Timmis
Journal: BMJ (2015)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Acute coronary syndromes Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Lung cancer
Authors: R. D. Neal, W. Hamilton, T. K. Rogers
Journal: BMJ (2014)

#### The bottom line A 65 year old recent ex-smoker with a 20 pack year history and chronic obstructive pulmonary disease (COPD) consults his general practitioner because of worse chest symptoms over the past three weeks, with increasing breathlessness and production of green sputum, and a feeling of being "off colour." Similar previous spells have been treated with antibiotics and steroids to good effect. On examination his temperature is normal, his heart rate is 88 beats/min, respiratory rate is 16 breaths/min, and oxygen saturation is 94% on air. He has tobacco stained fingers but no clubbing or evidence of weight loss. Scattered crackles and wheezes are found on auscultation of the lungs. After treatment with antibiotics and steroids he feels no better, and after two further consultations he is referred for chest radiography, which is reported as showing a lesion suspicious of lung cancer. #### How common is it?
Urban-Rural Disparity Trends in Aortic Aneurysm Mortality in the United States, 1999-2019
Authors: Keerat Rai Ahuja, Anas Qatanani, Abdul Mannan Khan Minhas, Robert W. Ariss, Asif Mahmood, Satish Kumar Ahuja, Rohit Vyas, Salik Nazir
Journal: Journal of the American College of Cardiology (2022)